Navigation Links
Tuberculosis still a risk for patients receiving HIV drugs

People taking highly active antiretroviral therapy (HAART) for HIV infection remain susceptible to tuberculosis, though the risk is lower than for HIV-infected patients not on HAART, according to an article in the Dec. 15 issue of Clinical Infectious Diseases, now available online.

Opportunistic infections such as tuberculosis (TB) can be fatal for immunocompromised patients. HAART not only reduces the viral load of HIV, but it also often helps to keep other infections such as TB under control. In fact, previous studies indicate that HAART can reduce the risk of TB in HIV patients by 70 to 90 percent. Although HIV-infected people living in industrialized nations are at lower risk of TB than those living in resource-poor countries, it continues to be a significant problem for HIV-infected people everywhere.

A group of European and American researchers followed patients with HIV for three years after they began HAART. The rate of tuberculosis was highest within the first three months of therapy, but declined after longer HAART exposure. Patients' risk of developing tuberculosis more than doubled if HAART did not successfully control their HIV. Patients were also more likely to develop TB if they were more immunodeficient when they started taking HAART.

HIV-infected patients from industrialized nations might develop TB if they were exposed to the tuberculosis organism in the past, especially for those emigrating from resource-poor countries. Their weakened immune status can allow reactivation of latent TB infection, according to lead author Enrico Girardi, MD, of the Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani in Rome.

But they don't necessarily have to leave the country to contract TB. HIV-infected American and European patients who are "exposed to someone with tuberculosis, for example in a hospital setting, are at increased risk of acquiring tuberculosis infection and of developing active tuberculosis within a s hort time, usually six months to one year," Dr. Girardi said.

Since TB is a potentially deadly opportunistic infection for patients with HIV, doctors need to be aware of the risk and take certain precautionary measures. "HIV-infected patients, even when treated with HAART, remain at increased risk of developing tuberculosis," Dr. Girardi said. "Thus, physicians caring for patients with HIV should continue to screen for and to treat latent tuberculosis infection in their patients, even if they have minor levels of immune suppression or are successfully treated with HAART." Health care settings should also maintain strict control measures to prevent the spread of tuberculosis to patients being treated for HIV, Dr. Girardi added.

In an accompanying editorial commentary, Stephen D. Lawn, MRCP, MD, and Robin Wood, MBChB, of the Desmond Tutu HIV Centre in South Africa indicated similar findings (unpublished) related to patients' immunological response to HAART and subsequent development of TB. The commentary concludes that HIV-infected patients' risk for infection with TB "remains elevated among those receiving treatment in both high- and low-income countries."


'"/>

Source:Infectious Diseases Society of America


Related biology news :

1. Boosting The BCG Vaccine To Beat Tuberculosis
2. Researchers Discover Ancient Origins Of Tuberculosis-causing Bacteria
3. Tuberculosis: The bacillus takes refuge in adipose cells
4. South Africa still debating how to tackle HIV/AIDS when 5 million are infected
5. Human brain is still evolving
6. Genetic testing still smart choice, despite uncertainties
7. DNA conclusive yet still controversial, Carnegie Mellon professor says
8. One-third of adults with diabetes still dont know they have it
9. Mice lacking key immune component still control chronic viral infections
10. Despite acidity, orange juice could still be a source of foodborne disease
11. Ten years later, Dolly is still making headlines
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... 2017 No two people are believed ... New York University Tandon School of Engineering and ... that partial similarities between prints are common enough ... phones and other electronic devices can be more ... lies in the fact that fingerprint-based authentication systems ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
Breaking Biology News(10 mins):
(Date:9/25/2017)... South Jordan, UT, and Portland, OR (PRWEB) , ... ... ... CallTower , an industry-leading Unified Communications (UC) and Collaboration ... cloud performance in real-time, announced today a strategic alliance to extend CallTower’s ...
(Date:9/25/2017)... ... 25, 2017 , ... Having met specific requirements for its ... found to provide product development services that consistently meet customer and ... have a lot at stake when they invest in developing medical ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... studies, presentations and demonstrations at SCDM 2017, held September 24-27, 2017 in ... teams and CRO partners for more automated capabilities across evolving data, Comprehend ...
(Date:9/22/2017)... Scottsdale, AZ (PRWEB) , ... September 22, 2017 ... ... announced that it recently raised nearly $200,000 via Kickstarter. The proceeds will be ... 623 backers pre-ordered the B2v2, exceeding the original Kickstarter goal by nearly 1,000%. ...
Breaking Biology Technology: